代谢适应驱动急性早幼粒细胞白血病对三氧化二砷耐药
该研究建立稳定的ATO耐药早幼粒细胞系,发现耐药细胞对ATRA及ATO联合ATRA敏感性降低,代谢通路显著失调;线粒体呼吸抑制剂与ATO联用可克服耐药,并在非M3 AML和复发APL中具潜在治疗价值。
要点
- ATO耐药APL细胞系存在代谢通路失调,糖酵解抑制不能影响耐药细胞。
- 线粒体呼吸靶向药物与ATO联用可显著影响耐药细胞,不受耐药突变或抗凋亡蛋白依赖模式影响。
- 该联合策略在非M3 AML和复发APL中具潜在治疗价值,需进一步临床探索。
核心结论
- 线粒体呼吸抑制剂(mitocans)与ATO联用可克服APL的ATO耐药。
- 该联合方案对非M3 AML和复发APL具潜在治疗价值。
研究设计与样本
- 研究建立稳定的ATO耐药早幼粒细胞系,并与敏感细胞系比较。
- 耐药细胞系在免疫表型、药物转运体表达、抗凋亡蛋白依赖及PML-RARA突变方面存在显著差异。
- 采用基因表达谱分析及体内可移植APL小鼠模型验证。
主要发现
- 耐药细胞系对ATRA及ATO联合ATRA的敏感性低于敏感细胞系。
- 耐药细胞系显示细胞代谢通路显著失调。
- 2-DG抑制糖酵解对敏感APL细胞系有效且与ATO标准治疗相当,在体内APL小鼠模型中也有效,但对ATO耐药细胞系无影响。
- 靶向线粒体呼吸的化合物与ATO联用可显著影响耐药细胞系,不受耐药遗传突变或抗凋亡蛋白依赖模式影响。
临床怎么用
- 对ATO耐药的APL,可考虑线粒体呼吸抑制剂与ATO联合策略。
- 该联合策略可能扩展至非M3 AML和复发APL的治疗。
- 临床转化需进一步探索。
局限性
- 耐药细胞系为体外建立,与临床耐药机制可能存在差异。
- 临床转化尚未验证,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acquired genetic mutations can confer resistance to arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL). However, such resistance-conferring mutations are rare and do not explain most disease recurrence seen in the clinic. We have generated stable ATO-resistant promyelocytic cell lines that are less sensitive to all-trans retinoic acid (ATRA) and the combination of ATO and ATRA compared with the sensitive cell line. Characterization of these resistant cell lines that were generated in-house showed significant differences in immunophenotype, drug transporter expression, anti-apoptotic protein dependence, and promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA) mutation. Gene expression profiling revealed prominent dysregulation of the cellular metabolic pathways in these ATO-resistant APL cell lines. Glycolytic inhibition by 2-deoxyglucose (2-DG) was sufficient and comparable to the standard of care (ATO) in targeting the sensitive APL cell line. 2-DG was also effective in the in vivo transplantable APL mouse model; however, it did not affect the ATO-resistant cell lines. In contrast, the resistant cell lines were significantly affected by compounds targeting mitochondrial respiration when combined with ATO, irrespective of the ATO resistance-conferring genetic mutations or the pattern of their anti-apoptotic protein dependency. Our data demonstrate that combining mitocans with ATO can overcome ATO resistance. We also show that this combination has potential for treating non-M3 acute myeloid leukemia (AML) and relapsed APL. The translation of this approach in the clinic needs to be explored further.
引用
- Balasundaram N, Ganesan S, Chendamarai E, et al. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia. Blood Adv. 2022. PMID: 34625794. doi:10.1182/bloodadvances.2021005300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。